[go: up one dir, main page]

EP1487850A2 - A building block forming a c-c or a c-hetero atom bond upon reaction - Google Patents

A building block forming a c-c or a c-hetero atom bond upon reaction

Info

Publication number
EP1487850A2
EP1487850A2 EP03711855A EP03711855A EP1487850A2 EP 1487850 A2 EP1487850 A2 EP 1487850A2 EP 03711855 A EP03711855 A EP 03711855A EP 03711855 A EP03711855 A EP 03711855A EP 1487850 A2 EP1487850 A2 EP 1487850A2
Authority
EP
European Patent Office
Prior art keywords
group
aryl
independently
alkylene
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03711855A
Other languages
German (de)
French (fr)
Inventor
Alex Haahr Gouliaev
Henrik Pedersen
Kim Birkebaerd Jensen
Mikkel Dybro Lundorf
Christian Sams
Jakob Felding
Michael Anders Godskesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuevolution AS
Original Assignee
Nuevolution AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevolution AS filed Critical Nuevolution AS
Publication of EP1487850A2 publication Critical patent/EP1487850A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Definitions

  • the present invention relates to a building block comprising a complementing element and a precursor for a functional entity.
  • the building block is designed to transfer the functional entity precursor with an adjustable efficiency to a recipient reactive group upon recognition between the complementing element and an encoding ele- ment associated with the reactive group.
  • the invention also relates to a method for transferring a functional entity precursor to recipient a reactive group.
  • the first oligonucleotide and a second oligonucleotide having a 3' amino group is aligned on a template such that the thioester group and the amino group are positioned in close proximity and a transfer is effected resulting in a coupling of the peptide to the second oligonucleotide through an amide bond.
  • the present invention relates to a building block of the general formula: Complementing Element - Linker - Carrier - C-F-connecting group - Functional entity precursor capable of transferring a Functional entity precursor to a recipient reactive group, wherein
  • Complementing Element is a group identifying the Functional entity precursor
  • Linker is a chemical moiety comprising a spacer and a S-C-connecting group, wherein the spacer is a valence bond or a group distancing the Functional entity precursor to be transferred from the complementing element and the S-C- connecting group connects the spacer with the Carrier
  • Carrier is arylene, heteroarylene, C C 6 alkylene, C-
  • C-F-connecting group is chosen from the group consisting of -SO 2 -O-, -O-SO 2 -O-, -C(O)-O-, -S + (R 3 RRrr)-, -C-U-C(V)-O-, -P + (W) 2 -O-, -P(W)-O- where U is
  • Functional entity precursor is -C(H)(R 3 )-R 4 or functional entity precursor is heteroaryl or aryl optionally substituted with one or more substituents belonging to the group comprising R 3 and R 4 .
  • C 3 -C 7 cycloheteroalkyl refers to a radical of totally saturated heterocycle like a cyclic hydrocarbon containing one or more heteroatoms selected from nitrogen, oxygen, phosphor, boron and sulphur independently in the cycle such as pyrrolidine (1- pyrrolidine; 2- pyrrolidine; 3- pyrrolidine; 4- pyr- rolidine; 5- pyrrolidine); pyrazolidine (1- pyrazolidine; 2- pyrazolidine; 3- pyra- zolidine; 4-pyrazolidine; 5-pyrazolidine); imidazolidine (1- imidazolidine; 2- imida- zolidine; 3- imidazolidine; 4- imidazolidine; 5- imidazolidine); thiazolidine (2- thia- zolidine; 3- thiazolidine; 4- thiazolidine; 5- thiazolidine); piperidine (1- piperidine; 2- piperidine; 3- piperidine; 4- piperidine;
  • Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems as well as up to four fused fused aromatic- or partially hydrogenated rings, each ring comprising 5-7 carbon atoms.
  • heteroaryl as used herein includes heterocyclic unsaturated ring systems containing, in addition to 2-18 carbon atoms, one or more heteroatoms selected from nitrogen, oxygen and sulphur such as furyl, thienyl, pyrrolyl, heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below.
  • aryl and “heteroaryl” as used herein refers to an aryl which can be op- tionally substituted or a heteroaryl which can be optionally substituted and includes phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N- hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1- anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl
  • the Functional Entity carries elements used to interact with host molecules and optionally reactive elements allowing further elaboration of an encoded molecule of a library. Interaction with host molecules like enzymes, receptors and polymers is typi- cally mediated through van der waal's interactions, polar- and ionic interactions and pi-stacking effects. Substituents mediating said effects may be masked by methods known to an individual skilled in the art (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis; 3rd ed.; John Wiley & Sons: New York, 1999.) to avoid undesired interactions or reactions during the preparation of the individual building blocks and during library synthesis. Analogously, reactive elements may be masked by suitably selected protection groups. It is appreciated by one skilled in the art that by suitable protection, a functional entity may carry a wide range of substi- tutents.
  • the Functional Entity Precursor is a masked. Functional Entity that is incorporated into an encoded molecule. After incorporation, reactive elements of the Functional Entity may be revealed by un-masking allowing further synthetic operations. Finally, elements mediating recognition of host molecules may be un-masked.
  • Functional entity precursor is -C(H)(R 1 )-R 11 ' or functional entity precursor is heteroaryl or aryl substituted with 0-3 R 11 , 0-3 R 13 and 0-3 R 15 , wherein
  • R 11 and R 11 ' are independently H, or selected among the group consisting of a C C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 4 -C 8 alkadienyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cyclo- heteroalkyl, aryl, and heteroaryl, said group being substituted with 0-3 R 12 , 0-3 R 13 and 0-3 R 15 , or R 11 and R 11 ' are C C 3 alkylene-NR 12 2 , C C 3 alkylene-NR 12 C(O)R 16 , d-C 3 al- kylene-NR 12 C(O)OR 16 , C C 2 alkylene-O-NR 12 2 , C C 2 alkylene-O-NR 12 C(O)R 16 ,
  • R 12 is H or selected independently among the group consisting of C C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloheteroalkyl, aryl, heteroaryl, said group being substituted with 0-3 R 13 and 0-3 R 15 ,
  • R 13 is selected independently from -N 3 , -CNO, -C(NOH)NH 2 , -NHOH,
  • R 14 where R 14 is independently selected from -NO 2 , -C(O)OR 17 , -COR 17 , -CN,
  • R 16 is H, C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, aryl or C ⁇ -C 6 alkylene-aryl substituted with 0-3 substituents independently selected from -F, -CI, -
  • R 17 is selected independently from H, C C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, C C 6 al-
  • the function of the carrier is to ensure the transferability of the functional entity precursor.
  • a skilled chemist can design suitable substitutions of the carrier by evaluation of initial attempts.
  • the transferability may be adjusted in response to the chemical composition of the functional entity precursor, to the nature of the complementing element, to the conditions under which the transfer and recognition is performed, etc.
  • the carrier is selected from the group consisting of ary- lene, heteroarylene or -(CF 2 ) m . substituted with 0-3 R 1 wherein m is an integer between 1 and 10, and C-F-connecting group is -SO 2 -O-. Due to the high reactivity of such compounds a broad range of recipient reactive groups may be employed in the construction of carbon-carbon bonds or carbon-hetero atom bonds.
  • the carrier is -(CF 2 ) m - wherein m is an integer between 1 and 10, the C-F-connecting group is -SO 2 -O-; and the func- tional entity precursor is aryl or heteroaryl substituted with 0-3 R 11 , 0-3 R 13 and 0-3 R 15 .
  • the C-F-connecting group determines in concert with the carrier the transferability of the functional entity precursor.
  • the C-F-connecting group is -S + (R 11 )-,
  • the C-F-connecting group is chosen from the group consisting of -SO 2 -O-, and -S + (R 17 )-; wherein R 17 is selected independently from H, C C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, C ⁇ -C 6 alkylene-aryl.
  • an aromatic moiety may be transferred from the C-F-connecting group to a recipient reactive group. Further, the transfer may be initiated by adding the catalyst, independently of the annealing of encoding - and complementing elements.
  • the S-C-connecting group provide a means for connecting the Spacer and the Carrier. As such it is primarily of synthetic convenience and does not influence the function of a building block.
  • the spacer serves to distance the functional entity precursor to be transferred from the bulky complementing element.
  • the identity of the spacer is not crucial for the function of the building block. It may be desired to have a spacer which can be cleaved by light. In this case, the spacer is provided with e.g. the group
  • the spacer may be provided with a polyethylene glycol part of the general formula:
  • the complementing element serves the function of trans- ferring genetic information e.g. by recognising a coding element.
  • the recognition implies that the two parts are capable of interacting in order to assemble a complementing element - coding element complex.
  • a variety of interacting molecular parts are known which can be used according to the invention. Examples include, but are not restricted to protein-protein interactions, protein- polysaccharide interactions, RNA-protein interactions, DNA-DNA interactions, DNA-
  • RNA interactions RNA-RNA interactions, biotin-streptavidin interactions, enzyme- ligand interactions, antibody-ligand interaction, protein-ligand interaction, etc.
  • the interaction between the complementing element and coding element may result in a strong or a weak bonding. If a covalent bond is formed between the parties of the affinity pair the binding between the parts can be regarded as strong, whereas the establishment of hydrogen bondings, interactions between hydrophobic do- mains, and metal chelation in general results in weaker bonding. In general relatively weak bonding is preferred.
  • the complementing element is capable of reversible interacting with the coding element so as to provide for an attachment or detachment of the parts in accordance with the chang- ing conditions of the media.
  • the interaction is based on nucleotides, i.e. the complementing element is a nucleic acid.
  • the complementing element is a sequence of nucleotides and the coding element is a sequence of nucleo- tides capable of hybridising to the complementing element.
  • the sequence of nucleotides carries a series of nucleobases on a backbone.
  • the nucleobases may be any chemical entity able to be specifically recognized by a complementing entity.
  • the nucleobases are usually selected from the natural nucleobases (adenine, guanine, uracil, thymine, and cytosine) but also the other nucleobases obeying the Watson- Crick hydrogen-bonding rules may be used, such as the synthetic nucleobases disclosed in US 6,037,120. Examples of natural and non-natural nucleobases able to perform a specific pairing are shown in figure 2.
  • the backbone of the sequence of nucleotides may be any backbone able to aggregate the nucleobases is a sequence. Examples of backbones are shown in figure 4. In some aspects of the in- vention the addition of non-specific nucleobases to the complementing element is advantegeous, figure 3
  • the coding element can be an oligonucleotide having nucleobases which complements and is specifically recognised by the complementing element, i.e. in the event the complementing element contains cytosine, the coding element part contains guanine and visa versa, and in the event the complementing element contains thymine or uracil the coding element contains adenine.
  • the complementing element may be a single nucleobase. In the generation of a library, this will allow for the incorporation of four different functional entities into the template-directed molecule. However, to obtain a higher diversity a complementing element preferably comprises at least two and more preferred at least three nucleotides. Theoretically, this will provide for 4 2 and 4 3 , respectively, different functional entities uniquely identified by the complementing element.
  • the complementing element will usually not comprise more than 100 nucleotides. It is preferred to have complementing elements with a sequence of 3 to 30 nucleotides.
  • the building blocks of the present invention can be used in a method for transferring a functional entity precursor to a recipient reactive group, said method comprising the steps of providing one or more building blocks as described above and contacting the one or more building blocks with a corresponding encoding element associated with a recipient reactive group under conditions which allow for a recognition between the one or more complementing elements and the encoding elements, said contacting being performed prior to, simultaneously with, or subse- quent to a transfer of the functional entity precursor to the recipient reactive group.
  • the encoding element may comprise one, two, three or more codons, i.e. sequences that may be specifically recognised by a complementing element.
  • Each of the codons may be separated by a suitable spacer group.
  • all or at least a majority of the codons of the template are arranged in sequence and each of the codons are separated from a neighbouring codon by a spacer group.
  • the number of codons of the encoding element is 2 to 100.
  • encoding elements comprising 3 to 10 codons.
  • a codon comprises 1 to 50 nucleotides and the complementing element comprises a sequence of nucleotides complementary to one or more of the encoding sequences.
  • the recipient reactive group may be associated with the encoding element in any appropriate way.
  • the reactive group may be associated covalently or non- covalently to the encoding element.
  • the recipient reactive group is linked covalently to the encoding element through a suitable linker which may be separately cleavable to release the reaction product.
  • the reactive group is coupled to a complementing element, which is capable of recognis- ing a sequence of nucleotides on the encoding element, whereby the recipient reactive group becomes attached to the encoding element by hybridisation.
  • the recipient reactive group may be part of a chemical scaffold, i.e. a chemical entity having one or more reactive groups available for receiving a functional entity precursor from a building block.
  • the recipient reactive group may be any group able to participate in cleaving the bond between the carrier and the functional entity precursor to release the functional entity precursor.
  • the recipient reactive group is a nucleophilic atom such as S, N, O, C or P.
  • Scheme 1a shows the transfer of an alkyl group and scheme 1b shows the transfer of an vinyl group.
  • the recipient reactive group is a organometallic compound as shown in scheme 2.
  • the building blocks are used for the formation of a library of compounds.
  • the complementing element of the building block is used to identify the functional entity. Due to the enhanced proximity between reactive groups when the complementing entity and the encoding element are contacted, the functional entity precursor together with the identity programmed in the complementing element is transferred to the encoding element associated with recipient reactive group.
  • the sequence of the complementing element is unique in the sense that the same sequence is not used for another functional entity.
  • the unique identification of the functional entity enable the possibility of decoding the encoding element in order to determine the synthetic history of the molecule formed. In the event two or more functional entities have been transferred to a scaffold, not only the identity of the transferred functional entities can be determined.
  • each different member of a library comprises a complementing element having a unique sequence of nucleotides, which identifies the functional entity.
  • FIG. 1 Two setups for Functional Entity Transfer Figure 2. Examples of specific base pairing Figure 3. Example of non-specific base-pairing Figure 4. Backbone examples Figure 5 Three examples of building blocks
  • a building block of the present invention is characterized by its ability to transfer its functional entity precursor to a recipient reactive group. This is done by forming a new covalent bond between the recipient reactive group and cleaving the bond between the carrier moiety and the functional entity precursor of the building block.
  • FIG. 1 Two setups for generalized functional entity precursor transfer from a building block are depicted in figure 1.
  • one complementing element of a build- ing block recognizes a coding element carrying another functional entity precursor, hence bringing the functional entities in close proximity. This results in a reaction between functional entity precursor 1 and 2 forming a covalent bond between these concurrent with the cleavage of the bond between functional entity precursor 2 and its linker.
  • a template brings together two building blocks re- suiting in functional entity precursor transfer from one building block to the other.
  • Figure 5 illustrates three specific compounds according to the invention. For illustrative purposes the individual features used in the claims are indicated.
  • the upper compound is an example of a building block wherein the linker is backbone attached at the 3'-position.
  • the first part of the linker i.e. the spacer, is an aliphatic chain ending in a nitrogen atom.
  • the nitrogen atom bridges to the S-C-connecting group, which is an N-acylated arylmethyleamine.
  • the carrier attached to the left hand side carbonyl group of the S-C-connecting group is a benzene ring holding the C-F Connecting group in the para position.
  • the C-F Connecting group is a positively charged sulfur atom which is attached to the Functional Entity Precursor, in this case a benzyl group.
  • the middle compound illustrates a 5' attachment of a linker.
  • the linker is linked through a phosphate group and extends into a three membered aliphatic chain. Through another phosphate group and a PEG linker the complementing element is linked via an amide bond to the Carrier.
  • the Functional Entity Precursor is transferred resulting in an alkylation of the nucleophile.
  • the lower compound illustrates a nucleobase attachment of the linker.
  • the linker attaches to the 5 position of a pyrimidine type nucleobase and extents through an ⁇ - ⁇ unsaturated N-methylated amide to the S-C-connecting group, which is a 4- amino methyl benzoic acid derivative.
  • the functional entity precursor can be transferred to a nucleophilic recipient reactive group e.g. an amine or a thiol forming an allylic amine or thiol.
  • the functional entity precursor is of the formula -C(H)(R 3 )-R 4 or functional entity precursor is heteroaryl or aryl optionally substituted with one or more substituents belonging to the group comprising R 3 and R 4 .
  • the functional entity precursor is of the formula -C(H)(R 3 )-R 4 or functional entity precursor is heteroaryl or aryl optionally substituted with one or more substituents belonging to the group comprising R 3 and R 4 .
  • R 5 , R 6 , R 7 and R 8 independently is H, C C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 4 -C 8 alkadienyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloheteroalkyl, aryl or heteroaryl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3- 8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, C C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cyclohet- eroalkyl, aryl or heteroaryl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, C C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cyclohet- eroalkyl, aryl or heteroaryl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, d-C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloheteroalkyl, aryl or heteroaryl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, C C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloheteroalkyl, aryl or heteroaryl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyc- lie ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, C C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloheteroalkyl, aryl or heteroaryl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring, in still another prefered embodiment,
  • R 5 , R 6 , R 7 and R 8 independently is H, C C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloheteroalkyl, aryl or heteroaryl and wherein R 5 and R 6 may together form a 3-8 mem- bered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R 5 and R 6 may together form a 3-8 membered het- erocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R
  • R 5 , R 6 , R 7 and R a independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R 5 and R 6 may together form a 3-8 membered het- erocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, methyl, ethyl, propyl or butyl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may to- gether form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, methyl, ethyl, propyl or butyl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, methyl, ethyl, propyl or butyl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, methyl, ethyl, propyl or butyl and wherein R 5 and R 6 may together form a 3-8 membered heterocyclic ring or R 5 and R 7 may together form a 3-8 membered heterocyclic ring or R 6 and R 7 may together form a 3-8 membered heterocyclic ring,
  • R 5 , R 6 , R 7 and R 8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl, in still another prefered embodiment,
  • R 5 , R 6 , R 7 and R 8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
  • R 5 , R 6 , R 7 and R 8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
  • R 3 and R 4 independently is H, C C 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloheteroalkyl, aryl or heteroaryl
  • R 3 and R 4 independently is H
  • R 3 and R 4 independently is C C 6 alkyl, C 3 -C 7 cycloalkyl or C 3 -C 7 cycloheteroalkyl,
  • R 3 and R 4 independently is methyl, ethyl, propyl or butyl
  • R 3 and R 4 independently is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl
  • R 3 and R 4 independently is aziridinyl, pyrrolidinyl, piperidinyl or morpholinyl
  • R 3 and R 4 independently is aryl or heteroaryl
  • R 3 and R 4 independently is phenyl or naphthyl
  • R 3 and R 4 independently is thienyl, furyl, pyridyl, quinolinyl or isoquinolyl
  • the 4-halobenzoic acid (25 mmol) is added to a ice cooled solution of chloro sulfo- nic acid (140 mmol). The mixture is slowly heated to reflux and left at reflux for 2-3 hours. The mixture is added to 100 mL ice and the precipitate collected by filtration. The filtrate is washed with water (2 x 50 mL) and the dried in vacuo affording the corresponding sulfonoyl chloride in 60-80% yield.
  • the 3-chlorosulfonyl-4-halo- benzoic acid derivate (5 mmol) is dissolved in EtOH (5 mL) and added to a ice cooled mixture of NaOEt (10 mL, 2M).
  • Ps Polystyrene resin. Alternatively other acid labile linkers may be employed.
  • Step l A polystyrene resin with a wang linker (4-hydroxymethylphenol linker) (50 mg ⁇ 50 umol), a bi-functional carrier (200 umol, 4 equiv) in a solvent such as THF, DCM, DCE, DMF, NMP or a mixture thereof (500 uL) and a base such as TEA, DIEA, pyri- dine (400 umol, 8 equiv), optionally in the presence of DMAP (100 umol), are allowed to react at temperatures between -20 °C and 60 °C, preferably between 0 °C and 25 °C, for 1-24 h, preferably 1-4 h. The resin is washed with the solvent compo- sition used during the reaction (5x1 mL) and used in the following step.
  • a solvent such as THF, DCM, DCE, DMF, NMP or a mixture thereof (500 uL) and a base such as TEA, DIEA
  • a functional entity precursor carrying a hydroxy group in the position of the intended attachment to the C-F-connecting group (200 umol, 4 equiv) in a solvent such as THF, DCM, DCE, DMF, NMP or a mixture thereof (500 uL) and a base such as TEA,
  • DIEA, pyridine (400 umol, 8 equiv), optionally in the presence of DMAP, are added to the resin bound carrier isolated in step 1 and allowed to react at temperatures between 0 °C and 100 °C, preferably between 25 °C and 80 °C, for 2-48 h, preferably 4-16 h.
  • the resin is washed with the solvent composition used during the reac- tion (5x1 mL).
  • the desired Carrier-Functional entity reagent is cleaved from the resin obtained in step 2 by treatment with an acid like TFA, HF or HCI in a solvent such as THF, DCM, DCE or a mixture thereof (1 mL) at temperatures between -20 °C and 60 °C, preferably between 0 °C and 25 °C, for 1-4 h, preferably 1-2 h.
  • a solvent such as THF, DCM, DCE or a mixture thereof
  • the Carrier-Functional entity reagent may be bound to the Spacer by several different reactions as illustrated below. Formation of an amide bond between a carboxylic acid of the Carrier and an amine group of a Spacer
  • 15 ⁇ L of a 150 mM building block solution of FE 1 -Carrier-COOH is mixed with 15 ⁇ L of a 150 mM solution of EDC and 15 ⁇ L of a 150 mM solution of N-hydroxy- succinimide (NHS) using solvents like DMF, DMSO, water, acetonitril, THF, DCM, methanol, ethanol or a mixture thereof.
  • the mixture is left for 15 min at 25°C.
  • 45 ⁇ L of an aminooligo (10 nmol) in 100 mM buffer at a pH between 5 and 10, preferably 6.0-7.5 is added and the reaction mixture is left for 2 hours at 25°C. Excess building block and organic by-products were removed by extraction with EtOAc (400 ⁇ L).
  • EtOAc Remaining EtOAc is evaporated in vacuo using a speedvac.
  • the building block is purified following elution through a BioRad micro-spin chromatography column, and analyzed by electron spray mass spectrometry (ES-MS).
  • Oligo A 5'-YACGATGGATGCTCCAGGTCGC
  • Funtional Entity-OH is a phenol, n is an integer between 3 and 6.
  • the reaction mixture from step 1 is added to a solution of an aminooligo (10 nmol) in 100 mM buffer at a pH between 5 and 10, preferably 6.0-7.5 optionally in the presence of NHS.
  • the reaction mixture is left for 2 hours at 25°C. Excess building block and organic by-products were removed by extraction with EtOAc (400 ⁇ L). Remaining EtOAc is evaporated in vacuo using a speedvac.
  • the building aminooligo is purified following elution through a BioRad micro-spin chromatography column, and analyzed by electron spray mass spectrometry (ES-MS). Use of building blocks
  • An oligonucleotide building block carrying functional entity FE 1 is combined at 2 ⁇ M final concentration with one equivalent of a complementary building block displaying a nucleophilic recipient group. Reaction proceeds at temperatures between 0 °C and 100 °C preferably between 15 °C-50 °C for 1-48 hours, preferably 10-20 hours in DMF, DMSO, water, acetonitril, THF, DCM, methanol, ethanol or a mixture thereof, pH buffered to 4-10, preferably 6-8. Organic by-products are removed by extraction with EtOAc, followed by evaporation of residual organic solvent for 10 min in vacuo. Pd catalyst is removed and oligonucleotides are isolated by eluting sample through a BioRad micro-spin chromatography column. Coupling efficiency is quantified by ES-MS analysis.
  • a carrier coupled functional entity oligo (Example 1) (250 pmol) was added to a scaffold oligo B (200 pmol) in 50 ⁇ l 100 mM MES, pH 6. The mixture was incubated overnight at 25 °C. Subsequently, the mixture was purified by gel filtration using a microspin column equilibrated with H 2 O and transfer of the functional entity was veri- fied by electron spray mass spectrometry (ES-MS). Transfer efficiency is expressed in percent and were calculated by dividing the abundance of scaffold oligo carrying transferred functional entities to total abundance of scaffold oligos (with and without transferred functional entities).
  • An oligonucleotide building block carrying functional entity FE 1 is combined at 2 ⁇ M final concentration with one equivalent of a complementary building block displaying a nucleophilic recipient group.
  • the reaction pro- ceeds at temperatures between 0 °C and 100 °C preferably between 15 °C-50 °C for 1-48 hours, preferably 10-20 hours in DMF, DMSO, water, acetonitrile, THF, DCM, methanol, ethanol or a mixture thereof, pH buffered to 4-10, preferably 6-8.
  • Organic by-products are removed by extraction with EtOAc, followed by evaporation of residual organic solvent for 10 min in vacuo.
  • Pd catalyst is removed and oligonu- cleotides are isolated by eluting sample through a BioRad micro-spin chromatogra- phy column. Coupling efficiency is quantified by ES-MS analysis.
  • R 1 H, Me, Et, iPr, CI, N0 2
  • R 2 H, Me, Et, iPr, CI, N0 2
  • R 1 and R 2 may be used to tune the reactivity of the sulphate to allow appropriate reactivity. Chloro and nitro substitution will increase reactivity. Alkyl groups will decrease reactivity. Ortho substituents to the sulphate will due to steric reasons direct incoming nucleophiles to attack the R-group selectively and avoid attack on sulphur. E.g.
  • 3-Aminophenol (6) is treated with maleic anhydride, followed by treatment with an acid e.g. H 2 SO 4 or P 2 O 5 and heat to yield the maleimide (7).
  • the ring closure to the maleimide may also be achieved when an acid stable O-protection group is used by treatment with or Ac 2 O with or without heating, followed by O-deprotection. Alternatively reflux in Ac 2 O, followed by O-deacetylation in hot water/dioxane to yield (7).
  • a thiol carrying oligonucleotide in buffer 50 mM MOPS or hepes or phosphate pH 7.5 is treated with a 1-100 mM solution and preferably 7.5 mM solution of the organic building block (9) in DMSO or alternatively DMF, such that the DMSO/DMF concentration is 5-50%, and preferably 10%.
  • the mixture is left for 1-16 h and preferably 2-4 h at 25 °C.
  • methylating monomer building block (10) To give the alkylating in this case methylating monomer building block (10).
  • reaction of the alkylating monomer building block (10) with an amine carrying monomer building block may be conducted as follows:
  • the oligonucleotides are annealed to the template by heating to 50 °C and cooled (2 °C/ second) to 30 °C. The mixture is then left o/n at a fluctuating temperature (10 °C for
  • a vinylating monomer building block may be prepared and used similarily as described above for an alkylating monomer building block.
  • the intermediate chlorosulphate is isolated and treated with an enolate or O-trialkylsilylenolate with or without the presence of fluoride.
  • the thiol carrying oligonucleotide in buffer 50 mM MOPS or hepes or phosphate pH 7.5 is treated with a 1-100 mM solution and preferably 7.5 mM solution of the organic building block (12) in DMSO or alternatively DMF, such that the DMSO/DMF concentration is 5-50%, and preferably 10%.
  • the mixture is left for 1-16 h and preferably 2-4 h at 25 °C.
  • the sulfonylenolate (13) may be used to react with amine carrying monomer building block to give an enamine (14a and/or 14b) or e.g. react with an carbanion to yield (15a and/or 15b).
  • enamine 14a and/or 14b
  • carbanion 15a and/or 15b
  • the reaction of the vinylating monomer building block (13) and an amine or nitroal- kyl carrying monomer building block may be conducted as follows:
  • the oligonucleotides are annealed to the template by heating to 50 °C and cooled (2 °C/ second) to 30 °C.
  • the mixture is then left o/n at a fluctuating temperature (10 °C for 1 second then 35 °C for 1 second), to yield template bound (14a/b or 15a/b).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A building block having the dual capabilities of transferring genetic information and functional entity precursor to a recipient reactive group is disclosed. The building block may be used in the generation of a single complex or libraries of different complexes, wherein the complex comprises an encoded molecule linked to an encoding element. Libraries of complexes are useful in the quest for pharmaceutically active compounds.

Description

Title
A BUILDING BLOCK FORMING A C-C OR C-HETERO ATOM BOND UPON REACTION.
Technical Field of the Invention
The present invention relates to a building block comprising a complementing element and a precursor for a functional entity. The building block is designed to transfer the functional entity precursor with an adjustable efficiency to a recipient reactive group upon recognition between the complementing element and an encoding ele- ment associated with the reactive group. The invention also relates to a method for transferring a functional entity precursor to recipient a reactive group.
Background
The transfer of a chemical entity from one mono-, di- or oligonucleotide to another has been considered in the prior art. Thus, N. M. Chung et al. (Biochim. Biophys. Acta,1971 , 228,536-543) used a poly(U) template to catalyse the transfer of an acetyi group from 3'-O-acetyladenosine to the 5'-OH of adenosine. The reverse transfer, i.e. the transfer of the acetyi group from a 5'-O-acetyladenosine to a 3'-OH group of another adenosine, was also demonstrated.
Walder et al. Proc. Natl. Acad. Sci. USA, 1979, 76, 51-55 suggest a synthetic procedure for peptide synthesis. The synthesis involves the transfer of nascent immobilized polypeptide attached to an oligonucleotide strand to a precursor amino acid attached to an oligonucleotide. The transfer comprises the chemical attack of the amino group of the amino acid precursor on the substitution labile peptidyl ester, which in turn results in an acyl transfer. It is suggested to attach the amino acid precursor to the 5' end of an oligonucleotide with a thiol ester linkage.
The transfer of a peptide from one oligonucleotide to another using a template is disclosed in Bruick RK et al. Chemistry & Biology, 1996, 3:49-56. The carboxy terminal of the peptide is initially converted to a thioester group and subsequently transformed to an activated thioester upon incubation with Ellman's reagent. The activated thioester is reacted with a first oligo, which is 5'-thiol-terminated, resulting in the formation of a thio-ester linked intermediate. The first oligonucleotide and a second oligonucleotide having a 3' amino group is aligned on a template such that the thioester group and the amino group are positioned in close proximity and a transfer is effected resulting in a coupling of the peptide to the second oligonucleotide through an amide bond.
Summary of the Invention
The present invention relates to a building block of the general formula: Complementing Element - Linker - Carrier - C-F-connecting group - Functional entity precursor capable of transferring a Functional entity precursor to a recipient reactive group, wherein
Complementing Element is a group identifying the Functional entity precursor,
Linker is a chemical moiety comprising a spacer and a S-C-connecting group, wherein the spacer is a valence bond or a group distancing the Functional entity precursor to be transferred from the complementing element and the S-C- connecting group connects the spacer with the Carrier
Carrier is arylene, heteroarylene, C C6 alkylene, C-|-C6 alkenylene, C C6 al- kynylene, or -(CF2)m- substituted with 0-3 R1 wherein m is an integer between 1 and 10; R1 are independently selected from -H, -OR2, -NR2 2, -Halogen, -NO2, -CN,
-C(Halogen)3, -C(O)R2, -C(O)NHR2, C(O)NR2 2, -NC(O)R2, -S(O)2NHR2, -S(O)2NR2 2, -S(O)2R2, -P(O)2-R2, -P(O)- R2, -S(O)- R2, P(O)-OR2, -S(O)-OR2, -N+R2 3, wherein R2 is H, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or aryl,
C-F-connecting group is chosen from the group consisting of -SO2-O-, -O-SO2-O-, -C(O)-O-, -S+(R3RRrr)-, -C-U-C(V)-O-, -P+(W)2-O-, -P(W)-O- where U is
-C(R2)2-, -NR2- or -O-; V is =O or =NR2 and W is -OR2 or -N(R2)2
Functional entity precursor is -C(H)(R3)-R4 or functional entity precursor is heteroaryl or aryl optionally substituted with one or more substituents belonging to the group comprising R3 and R4.
Wherein R3 and R4 independently is H, alkyl, alkenyl, alkynyl, alkadienyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of SnR5R6R7, Sn(OR5)R6R7, Sn(OR5)(OR6)R7, BR5R6, B(OR5)R6, B(OR5)(OR6), halogen, CN, CNO, C(halogen)3, OR5, OC(=O)R5, OC(=O)OR5, OC(=O)NR5R6, SR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, N3, NR5R6, N+R5R6R7, NR5OR6, NR5NR6R7, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, NC, P(=O)(OR5)OR6, P+R5R6R7, C(=O)R5, C(=NR5)R6, C(=NOR5)R6, C(=NNR5R6), C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6, C(=O)NR5NR6R7, C(=NR5)NR6R7, C(=NOR5)NR6R7 or R8, wherein,
R5, R6, and R7 independently is H, alkyl, alkenyl, alkynyl, alkadienyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of halogen, CN, CNO, C(halogen)3, =O, OR8, OC(=O)R8, OC(=O)OR8, OC(=O)NR8R9, SR8, S(=O)R8, S(=O)2R8,
S(=O)2NR8R9, NO2, N3, NR8R9, N+R8R9R10, NR5OR6, NR5NR6R7, NR8C(=O)R9, NR8C(=O)OR9, NR8C(=O)NR9R10, NC, P(=O)(OR8)OR9, P+R5R6R7, C(=O)R8, C(=NR8)R9, C(=NOR8)R9, C(=NNR8R9), C(=O)OR8, C(=O)NR8R9, C(=O)NR8OR9 C(=NR5)NR6R7, C(=NOR5)NR6R7or C(=O)NR8NR9R10, wherein R5 and R6 may to- gether form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring, wherein, R8, R9, and R10 independently is H, alkyl, alkenyl, alkynyl, alkadienyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl and wherein R8 and R9 may together form a 3-8 membered heterocyclic ring or R8 and R10 may together form a 3-8 membered heterocyclic ring or R9 and R10 may together form a 3-8 membered heterocyclic ring.
In the present description and claims, the direction of connections between the various components of a building block should be read left to right. For example an S-C- connecting group -C(=O)-NH- is connected to a Spacer through the carbon atom on the left and to a Carrier through the nitrogen atom on the right hand side.
The term "C3-C7 cycloheteroalkyl" as used herein refers to a radical of totally saturated heterocycle like a cyclic hydrocarbon containing one or more heteroatoms selected from nitrogen, oxygen, phosphor, boron and sulphur independently in the cycle such as pyrrolidine (1- pyrrolidine; 2- pyrrolidine; 3- pyrrolidine; 4- pyr- rolidine; 5- pyrrolidine); pyrazolidine (1- pyrazolidine; 2- pyrazolidine; 3- pyra- zolidine; 4-pyrazolidine; 5-pyrazolidine); imidazolidine (1- imidazolidine; 2- imida- zolidine; 3- imidazolidine; 4- imidazolidine; 5- imidazolidine); thiazolidine (2- thia- zolidine; 3- thiazolidine; 4- thiazolidine; 5- thiazolidine); piperidine (1- piperidine; 2- piperidine; 3- piperidine; 4- piperidine; 5- piperidine; 6- piperidine); piperazine (1- piperazine; 2- piperazine; 3- piperazine; 4- piperazine; 5- piperazine; 6- piperazine); morpholine (2- morpholine; 3- morpholine; 4- morpholine; 5- mor- pholine; 6- morpholine); thiomorpholine (2- thiomorpholine; 3- thiomorpholine; 4- thiomorpholine; 5- thiomorpholine; 6- thiomorpholine); 1 ,2-oxathiolane (3-(1 ,2- oxathiolane); 4-(1 ,2-oxathiolane); 5-(1 ,2-oxathiolane); 1 ,3-dioxolane (2-(1 ,3- dioxolane); 4-(1,3-dioxolane); 5-(1,3-dioxolane); tetrahydropyrane; (2- tetrahydropyrane; 3-tetrahydropyrane; 4-tetrahydropyrane; 5-tetrahydropyrane; 6- tetrahydropyrane); hexahydropyridazine (l-(hexahydropyridazine); 2- (hexahydropyridazine); 3-(hexahydropyridazine); 4-(hexahydropyridazine); 5- (hexahydropyridazine); δ-(hexahydropyridazine)), [1 ,3,2]dioxaborolane, [1 ,3,6,2]dioxazaborocane The term "aryl" as used herein includes carbocyclic aromatic ring systems of 5-7 carbon atoms. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems as well as up to four fused fused aromatic- or partially hydrogenated rings, each ring comprising 5-7 carbon atoms. The term "heteroaryl" as used herein includes heterocyclic unsaturated ring systems containing, in addition to 2-18 carbon atoms, one or more heteroatoms selected from nitrogen, oxygen and sulphur such as furyl, thienyl, pyrrolyl, heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below. The terms "aryl" and "heteroaryl" as used herein refers to an aryl which can be op- tionally substituted or a heteroaryl which can be optionally substituted and includes phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N- hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1- anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3- pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), tria- zolyl (1 ,2,3-triazol-1-yl, 1 ,2,3-triazol-2-yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxa- zolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5- thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-py midinyl, 4- pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3- pyridazinyl, 4- pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6- quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4- isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5- benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl
(2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro- benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3- benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6- benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl (2-(2,3- dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro- benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro- benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2- indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3- indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1- benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6- benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1- benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1 -carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepine (5H- dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H- dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H- dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H- dibenz[b,f]azepine-2-yl, 10,11 -dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11 -dihydro- 5H-dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl).
The Functional Entity carries elements used to interact with host molecules and optionally reactive elements allowing further elaboration of an encoded molecule of a library. Interaction with host molecules like enzymes, receptors and polymers is typi- cally mediated through van der waal's interactions, polar- and ionic interactions and pi-stacking effects. Substituents mediating said effects may be masked by methods known to an individual skilled in the art (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis; 3rd ed.; John Wiley & Sons: New York, 1999.) to avoid undesired interactions or reactions during the preparation of the individual building blocks and during library synthesis. Analogously, reactive elements may be masked by suitably selected protection groups. It is appreciated by one skilled in the art that by suitable protection, a functional entity may carry a wide range of substi- tutents.
The Functional Entity Precursor is a masked. Functional Entity that is incorporated into an encoded molecule. After incorporation, reactive elements of the Functional Entity may be revealed by un-masking allowing further synthetic operations. Finally, elements mediating recognition of host molecules may be un-masked.
In a certain aspect of the invention, Functional entity precursor is -C(H)(R 1)-R11' or functional entity precursor is heteroaryl or aryl substituted with 0-3 R11, 0-3 R13 and 0-3 R15, wherein
R11 and R11' are independently H, or selected among the group consisting of a C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C4-C8 alkadienyl, C3-C7 cycloalkyl, C3-C7 cyclo- heteroalkyl, aryl, and heteroaryl, said group being substituted with 0-3 R12, 0-3 R13 and 0-3 R15, or R11 and R11' are C C3 alkylene-NR12 2, C C3 alkylene-NR12C(O)R16, d-C3 al- kylene-NR12C(O)OR16, C C2 alkylene-O-NR12 2, C C2 alkylene-O-NR12C(O)R16,
C C2 alkylene-O-NR12C(O)OR16 substituted with 0-3 R15, where R12 is H or selected independently among the group consisting of C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, heteroaryl, said group being substituted with 0-3 R13 and 0-3 R15,
R13 is selected independently from -N3, -CNO, -C(NOH)NH2, -NHOH,
-NHNHR17, -C(O)R17, -SnR17 3, -B(OR17)2, -P(O)(OR17)2 or the group consisting of C2-C6 alkenyl, C2-C6 alkynyl, C -C8 alkadienyl said group being substituted with 0-2
R14, where R14 is independently selected from -NO2, -C(O)OR17, -COR17, -CN,
-OSiR173, -OR17 and -NR17 2;
R15 is =O, -F, -CI, -Br, -I, -CN, -NO2, -OR17, -NR17 2, -NR17-C(O)R16, -NR17-C(O)OR16, -SR17, -S(O)R17, -S(O)2R17, -COOR17, -C(O)NR17 2 and -S(O)2NR17 2,
R16 is H, CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, aryl or Cι-C6 alkylene-aryl substituted with 0-3 substituents independently selected from -F, -CI, -
NO2, -R2, -OR2, -SiR2 3; R17 is selected independently from H, C C6 alkyl, C3-C7 cycloalkyl, aryl, C C6 al-
kylene-aryl, oorr , GG iiss HH or C C6 alkyl and n is 1 ,2,3 or 4.
The function of the carrier is to ensure the transferability of the functional entity precursor. To adjust the transferability a skilled chemist can design suitable substitutions of the carrier by evaluation of initial attempts. The transferability may be adjusted in response to the chemical composition of the functional entity precursor, to the nature of the complementing element, to the conditions under which the transfer and recognition is performed, etc.
In a preferred embodiment, the carrier is selected from the group consisting of ary- lene, heteroarylene or -(CF2)m. substituted with 0-3 R1 wherein m is an integer between 1 and 10, and C-F-connecting group is -SO2-O-. Due to the high reactivity of such compounds a broad range of recipient reactive groups may be employed in the construction of carbon-carbon bonds or carbon-hetero atom bonds.
In another preferred embodiment of the invention, the carrier is -(CF2)m- wherein m is an integer between 1 and 10, the C-F-connecting group is -SO2-O-; and the func- tional entity precursor is aryl or heteroaryl substituted with 0-3 R11, 0-3 R13 and 0-3 R15.
The C-F-connecting group determines in concert with the carrier the transferability of the functional entity precursor. In a preferred embodiment, the C-F-connecting group is -S+(R11)-,
In another preferred embodiment, the C-F-connecting group is chosen from the group consisting of -SO2-O-, and -S+(R17)-; wherein R17 is selected independently from H, C C6 alkyl, C3-C7 cycloalkyl, aryl, Cι-C6 alkylene-aryl.
In the presence of a catalyst comprising transition metals such as Pd, Ni or Cu, an aromatic moiety may be transferred from the C-F-connecting group to a recipient reactive group. Further, the transfer may be initiated by adding the catalyst, independently of the annealing of encoding - and complementing elements. The S-C-connecting group provide a means for connecting the Spacer and the Carrier. As such it is primarily of synthetic convenience and does not influence the function of a building block.
The spacer serves to distance the functional entity precursor to be transferred from the bulky complementing element. Thus, when present, the identity of the spacer is not crucial for the function of the building block. It may be desired to have a spacer which can be cleaved by light. In this case, the spacer is provided with e.g. the group
In the event an increased hydrophilicity is desired the spacer may be provided with a polyethylene glycol part of the general formula:
In a preferred embodiment, the complementing element serves the function of trans- ferring genetic information e.g. by recognising a coding element. The recognition implies that the two parts are capable of interacting in order to assemble a complementing element - coding element complex. In the biotechnological field a variety of interacting molecular parts are known which can be used according to the invention. Examples include, but are not restricted to protein-protein interactions, protein- polysaccharide interactions, RNA-protein interactions, DNA-DNA interactions, DNA-
RNA interactions, RNA-RNA interactions, biotin-streptavidin interactions, enzyme- ligand interactions, antibody-ligand interaction, protein-ligand interaction, etc.
The interaction between the complementing element and coding element may result in a strong or a weak bonding. If a covalent bond is formed between the parties of the affinity pair the binding between the parts can be regarded as strong, whereas the establishment of hydrogen bondings, interactions between hydrophobic do- mains, and metal chelation in general results in weaker bonding. In general relatively weak bonding is preferred. In a preferred aspect of the invention, the complementing element is capable of reversible interacting with the coding element so as to provide for an attachment or detachment of the parts in accordance with the chang- ing conditions of the media.
In a preferred aspect of the invention, the interaction is based on nucleotides, i.e. the complementing element is a nucleic acid. Preferably, the complementing element is a sequence of nucleotides and the coding element is a sequence of nucleo- tides capable of hybridising to the complementing element. The sequence of nucleotides carries a series of nucleobases on a backbone. The nucleobases may be any chemical entity able to be specifically recognized by a complementing entity. The nucleobases are usually selected from the natural nucleobases (adenine, guanine, uracil, thymine, and cytosine) but also the other nucleobases obeying the Watson- Crick hydrogen-bonding rules may be used, such as the synthetic nucleobases disclosed in US 6,037,120. Examples of natural and non-natural nucleobases able to perform a specific pairing are shown in figure 2. The backbone of the sequence of nucleotides may be any backbone able to aggregate the nucleobases is a sequence. Examples of backbones are shown in figure 4. In some aspects of the in- vention the addition of non-specific nucleobases to the complementing element is advantegeous, figure 3
The coding element can be an oligonucleotide having nucleobases which complements and is specifically recognised by the complementing element, i.e. in the event the complementing element contains cytosine, the coding element part contains guanine and visa versa, and in the event the complementing element contains thymine or uracil the coding element contains adenine.
The complementing element may be a single nucleobase. In the generation of a library, this will allow for the incorporation of four different functional entities into the template-directed molecule. However, to obtain a higher diversity a complementing element preferably comprises at least two and more preferred at least three nucleotides. Theoretically, this will provide for 42 and 43, respectively, different functional entities uniquely identified by the complementing element. The complementing element will usually not comprise more than 100 nucleotides. It is preferred to have complementing elements with a sequence of 3 to 30 nucleotides. The building blocks of the present invention can be used in a method for transferring a functional entity precursor to a recipient reactive group, said method comprising the steps of providing one or more building blocks as described above and contacting the one or more building blocks with a corresponding encoding element associated with a recipient reactive group under conditions which allow for a recognition between the one or more complementing elements and the encoding elements, said contacting being performed prior to, simultaneously with, or subse- quent to a transfer of the functional entity precursor to the recipient reactive group.
The encoding element may comprise one, two, three or more codons, i.e. sequences that may be specifically recognised by a complementing element. Each of the codons may be separated by a suitable spacer group. Preferably, all or at least a majority of the codons of the template are arranged in sequence and each of the codons are separated from a neighbouring codon by a spacer group. Generally, it is preferred to have more than two codons on the template to allow for the synthesis of more complex encoded molecules. In a preferred aspect of the invention the number of codons of the encoding element is 2 to 100. Still more preferred are encoding elements comprising 3 to 10 codons. In another aspect, a codon comprises 1 to 50 nucleotides and the complementing element comprises a sequence of nucleotides complementary to one or more of the encoding sequences.
The recipient reactive group may be associated with the encoding element in any appropriate way. Thus, the reactive group may be associated covalently or non- covalently to the encoding element. In one embodiment the recipient reactive group is linked covalently to the encoding element through a suitable linker which may be separately cleavable to release the reaction product. In another embodiment, the reactive group is coupled to a complementing element, which is capable of recognis- ing a sequence of nucleotides on the encoding element, whereby the recipient reactive group becomes attached to the encoding element by hybridisation. Also, the recipient reactive group may be part of a chemical scaffold, i.e. a chemical entity having one or more reactive groups available for receiving a functional entity precursor from a building block. The recipient reactive group may be any group able to participate in cleaving the bond between the carrier and the functional entity precursor to release the functional entity precursor. Typically, the recipient reactive group is a nucleophilic atom such as S, N, O, C or P. Scheme 1a shows the transfer of an alkyl group and scheme 1b shows the transfer of an vinyl group.
Scheme 1a
Nu = Oxygen- , Nitrogen- , Sulfur- and Carbon Nucleophiles
Scheme 1 b
Z = CN, COOR, COR, N02, S02R, S(=0)R, S02NR2, F Nu = Oxygen- , Nitrogen- , Sulfur- and Carbon Nucleophiles
Alternatively, the recipient reactive group is a organometallic compound as shown in scheme 2. Scheme 2
According to a preferred aspect of the invention the building blocks are used for the formation of a library of compounds. The complementing element of the building block is used to identify the functional entity. Due to the enhanced proximity between reactive groups when the complementing entity and the encoding element are contacted, the functional entity precursor together with the identity programmed in the complementing element is transferred to the encoding element associated with recipient reactive group. Thus, it is preferred that the sequence of the complementing element is unique in the sense that the same sequence is not used for another functional entity. The unique identification of the functional entity enable the possibility of decoding the encoding element in order to determine the synthetic history of the molecule formed. In the event two or more functional entities have been transferred to a scaffold, not only the identity of the transferred functional entities can be determined. Also the sequence of reaction and the type of reaction involved can be determined by decoding the encoding element. Thus, according to a preferred embodiment of the invention, each different member of a library comprises a complementing element having a unique sequence of nucleotides, which identifies the functional entity.
Brief description of the drawings
Figure 1. Two setups for Functional Entity Transfer Figure 2. Examples of specific base pairing Figure 3. Example of non-specific base-pairing Figure 4. Backbone examples Figure 5 Three examples of building blocks
Detailed Description of the Invention
A building block of the present invention is characterized by its ability to transfer its functional entity precursor to a recipient reactive group. This is done by forming a new covalent bond between the recipient reactive group and cleaving the bond between the carrier moiety and the functional entity precursor of the building block.
Two setups for generalized functional entity precursor transfer from a building block are depicted in figure 1. In the first example, one complementing element of a build- ing block recognizes a coding element carrying another functional entity precursor, hence bringing the functional entities in close proximity. This results in a reaction between functional entity precursor 1 and 2 forming a covalent bond between these concurrent with the cleavage of the bond between functional entity precursor 2 and its linker. In the second example, a template brings together two building blocks re- suiting in functional entity precursor transfer from one building block to the other. Figure 5 illustrates three specific compounds according to the invention. For illustrative purposes the individual features used in the claims are indicated. The upper compound is an example of a building block wherein the linker is backbone attached at the 3'-position. The first part of the linker, i.e. the spacer, is an aliphatic chain ending in a nitrogen atom. The nitrogen atom bridges to the S-C-connecting group, which is an N-acylated arylmethyleamine. The carrier attached to the left hand side carbonyl group of the S-C-connecting group is a benzene ring holding the C-F Connecting group in the para position. The C-F Connecting group is a positively charged sulfur atom which is attached to the Functional Entity Precursor, in this case a benzyl group. When the building block is presented to a nucleophilic recipient reactive group, such an amine or a thiol, Functional Entity Precursor is transferred to benzy- late the recipient reactive group.
The middle compound illustrates a 5' attachment of a linker. The linker is linked through a phosphate group and extends into a three membered aliphatic chain. Through another phosphate group and a PEG linker the complementing element is linked via an amide bond to the Carrier. When the building block is presented to a nucleophile the Functional Entity Precursor is transferred resulting in an alkylation of the nucleophile.
The lower compound illustrates a nucleobase attachment of the linker. The linker attaches to the 5 position of a pyrimidine type nucleobase and extents through an α - β unsaturated N-methylated amide to the S-C-connecting group, which is a 4- amino methyl benzoic acid derivative. The functional entity precursor can be transferred to a nucleophilic recipient reactive group e.g. an amine or a thiol forming an allylic amine or thiol.
According to the invention, the functional entity precursor is of the formula -C(H)(R3)-R4 or functional entity precursor is heteroaryl or aryl optionally substituted with one or more substituents belonging to the group comprising R3 and R4. In a further preferred embodiment,
R3 and R4 independently is H, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C4-C8 alkadienyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl, optionally sub- stituted with one or more substituents selected from the group consisting of SnR5Rβ,R7, Sn(OR5)R6R7, Sn(OR5)(OR6)R7, BR5R6, B(OR5)R6, B(OR5)(OR6), halogen, CN, CNO, C(halogen)3, =O, OR5, OC(=O)R5, OC(=O)OR5, OC(=O)NR5R6, SR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, N3, NR5R6, N+R5R6R7, NR5OR6, NR5NR6R7, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, NC, P(=O)(OR5)OR6, P+R5R6R7, C(=O)R5, C(=NR5)R6, C(=NOR5)R6, C(=NNR5R6), C(=O)OR5, C(=O)NR5R6,
C(=O)NR5OR6, C(=O)NR5NR6R7, C(=NR5)NR6R7, C(=NOR5)NR6R7 or R8, wherein,
R5, R6, R7 and R8 independently is H, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C4-C8 alkadienyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3- 8 membered heterocyclic ring,
in another prefered embodiment, R3 and R4 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of halogen, CN, C(halogen)3, =O, OR5, OC(=O)R5, OC(=O)OR5, OC(=O)NR5R6, SR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5OR6, NR5NR6R7, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, P(=O)(OR5)OR6, C(=O)R5, C(=NR5)R6, C(=NOR5)R6, C(=NNR5R6), C(=O)OR5,
C(=O)NR5R6, C(=O)NR5OR6, C(=O)NR5NR6R7, C(=NR5)NR6R7, C(=NOR5)NR6R7 or
R8, wherein,
R5, R6, R7 and R8 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cyclohet- eroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment, R3 and R4 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, OC(=O)R5, OC(=O)OR5, OC(=O)NR5R6, SR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5OR6, NR5NR6R7, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, P(=O)(OR5)OR6, C(=O)R5, C(=NR5)R6, C(=NOR5)R6, C(=NNR5R6), C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6, C(=O)NR5NR6R7, C(=NR5)NR6R7, C(=NOR5)NR6R7 or R8, wherein,
R5, R6, R7 and R8 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cyclohet- eroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment, R3 and R4 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)Rs, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, d-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, phenyl, naphtyl, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein, R5, R6, R7 and R8 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment, R3 and R4 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyc- lie ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl or mor- pholinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2,
NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein, R5, R6, R7 and R8 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cyclohet- eroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment, R3 and R4 independently is H, phenyl, naphtyl, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring, in still another prefered embodiment,
R3 and R4 independently is H, phenyl or naphtyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 mem- bered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl op- tionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein, R5, R6, R7 and R8 independently is H, d-C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R5 and R6 may together form a 3-8 membered het- erocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment, R3 and R4 independently is H, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl or mor- pholinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, phenyl, naphtyl, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6,
NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein, R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, phenyl or naphtyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and Ra independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R5 and R6 may together form a 3-8 membered het- erocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl op- tionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein, R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, thienyl, furyl, pyridinyl, quinolinyl or isoquinolinyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7,
C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl or butyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may to- gether form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl or mor- pholinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein, R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl or butyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, phenyl, naphtyl, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl or butyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is H, phenyl or naphtyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6,
NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl or butyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment, R3 and R4 independently is H, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, methyl, ethyl, propyl or butyl and wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring,
in still another prefered embodiment,
R3 and R4 independently is methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted with one or more substituents se- lected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5,
S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7,
C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
in still another prefered embodiment,
R3 and R4 independently is aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl or mor- pholinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2,
NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6,
C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
in still another prefered embodiment,
R3 and R4 independently is phenyl, naphtyl, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
in still another prefered embodiment,
R3 and R4 independently is phenyl or naphtyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6,
NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
in still another prefered embodiment,
R3 and R4 independently is thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6,
NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6,
C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, cyclopropyl, cyclobutyl, cyclopentyl or cyclo- hexyl,
in still another prefered embodiment,
R3 and R4 independently is methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl optionally substituted with one or more substituents se- lected from the group consisting of F, CI, CN, CF3, =O,βOR5, S(=O)R5, S(=O)2R5,
S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7,
C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl, in still another prefered embodiment,
R3 and R4 independently is aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl or mor- pholinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2,
NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
in still another prefered embodiment,
R3 and R4 independently is phenyl, naphtyl, thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6,
NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein, R5, R6, R7 and R8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
in still another prefered embodiment,
R3 and R4 independently is phenyl or naphtyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6,
NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
in still another prefered embodiment,
R3 and R4 independently is thienyl, furyl, pyridyl, quinolinyl or isoquinolinyl optionally substituted with one or more substituents selected from the group consisting of F, CI, CN, CF3, =O, OR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, NR5R6, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, C(=O)R5, C(=NOR5)R6, C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6 or R8, wherein,
R5, R6, R7 and R8 independently is H, phenyl, naphthyl, thienyl, furyl, pyridinyl, qui- nolinyl or isoquinolinyl,
in still another prefered embodiment,
R3 and R4 independently is H, C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl or heteroaryl
in still another prefered embodiment, R3 and R4 independently is H,
in still another prefered embodiment, R3 and R4 independently is C C6 alkyl, C3-C7 cycloalkyl or C3-C7 cycloheteroalkyl,
in still another prefered embodiment,
R3 and R4 independently is methyl, ethyl, propyl or butyl
in still another prefered embodiment
R3 and R4 independently is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl
in still another prefered embodiment
R3 and R4 independently is aziridinyl, pyrrolidinyl, piperidinyl or morpholinyl
in still another prefered embodiment,
R3 and R4 independently is aryl or heteroaryl
in still another prefered embodiment, R3 and R4 independently is phenyl or naphthyl
in still another prefered embodiment,
R3and R4 independently is thienyl, furyl, pyridyl, quinolinyl or isoquinolyl Experimental section
General Procedure 1 : Preparation of Carrier-Functional entity reagents:
The 4-halobenzoic acid (25 mmol) is added to a ice cooled solution of chloro sulfo- nic acid (140 mmol). The mixture is slowly heated to reflux and left at reflux for 2-3 hours. The mixture is added to 100 mL ice and the precipitate collected by filtration. The filtrate is washed with water (2 x 50 mL) and the dried in vacuo affording the corresponding sulfonoyl chloride in 60-80% yield. The 3-chlorosulfonyl-4-halo- benzoic acid derivate (5 mmol) is dissolved in EtOH (5 mL) and added to a ice cooled mixture of NaOEt (10 mL, 2M). The mixture is stirred o/n at rt. Acetic acid (40 mmol) is added and the mixture is evaporated in vacuo. Water (10 mL) is added and pH adjusted to pH = 2 (using 1 M HCI). The product is extracted with DCM (2 x25 mL), dried over Na2SO4 and evaporated in vacuo affording the desired products.
Example 1 (General procedure (1)) 3-Ethoxysulfonyl-4-fluorobenzoic acid
1H-NMR (DMSO-d6): δ 8.49 (d, 1H), 7.85 (dd, 1 H), 7.5 (d, 1 H), 4.32 (q, 2H), 1.32 (t, 3H)
Example 2 (General procedure (1))
4-chloro-3-Ethoxysulfonylbenzoic acid
1H-NMR (DMSO-d6): δ 8.49 (d, 1H), 7.85 (dd, 1 H), 7.5 (d, 1H), 4.32 (q, 2H), 1.32 (t, 3H) Example 3
4-Methylsulfanyl benzoic acid (0.5g, 2.97 mmol, commercially available from Aldrich, cat no. 145521) was added to methyl p-toluene solfunate (0.61g, 3.27 mmol). The mixture was heated to 140 °C for 1 hour in a sealed vessel. After cooling to rt the mixture was trituated with diethyl ether. Filtration and drying in vacuo yielded 844 mg (80%) of the desired product (>95% pure by 1H nmr).
1H nmr (DMSO-d6): 8.20-8.10 (m, 4H), 7.45 (d, 2H), 7.08 (d, 2H), 3.29 (s, 6H), 2.30 (s, 3H).
General Procedure 2: Solid phase preparation of Carrier-Functional entity reagents for alkylation building blocks:
O O HCr X arrie S N 0°
I
Functional Entity
Ps = Polystyrene resin. Alternatively other acid labile linkers may be employed.
Step l : A polystyrene resin with a wang linker (4-hydroxymethylphenol linker) (50 mg ~ 50 umol), a bi-functional carrier (200 umol, 4 equiv) in a solvent such as THF, DCM, DCE, DMF, NMP or a mixture thereof (500 uL) and a base such as TEA, DIEA, pyri- dine (400 umol, 8 equiv), optionally in the presence of DMAP (100 umol), are allowed to react at temperatures between -20 °C and 60 °C, preferably between 0 °C and 25 °C, for 1-24 h, preferably 1-4 h. The resin is washed with the solvent compo- sition used during the reaction (5x1 mL) and used in the following step.
Step 2:
A functional entity precursor carrying a hydroxy group in the position of the intended attachment to the C-F-connecting group (200 umol, 4 equiv) in a solvent such as THF, DCM, DCE, DMF, NMP or a mixture thereof (500 uL) and a base such as TEA,
DIEA, pyridine (400 umol, 8 equiv), optionally in the presence of DMAP, are added to the resin bound carrier isolated in step 1 and allowed to react at temperatures between 0 °C and 100 °C, preferably between 25 °C and 80 °C, for 2-48 h, preferably 4-16 h. The resin is washed with the solvent composition used during the reac- tion (5x1 mL).
Step 3:
The desired Carrier-Functional entity reagent is cleaved from the resin obtained in step 2 by treatment with an acid like TFA, HF or HCI in a solvent such as THF, DCM, DCE or a mixture thereof (1 mL) at temperatures between -20 °C and 60 °C, preferably between 0 °C and 25 °C, for 1-4 h, preferably 1-2 h. Upon filtration, the resin is washed with the solvent composition used during cleavage (2x1 mL) and the combined filtrates are evaporated in vacuo. The isolated product may be purified by chromatography.
Assembly of building blocks
The Carrier-Functional entity reagent may be bound to the Spacer by several different reactions as illustrated below. Formation of an amide bond between a carboxylic acid of the Carrier and an amine group of a Spacer
General Procedure 3: Preparation of building blocks by loading a Carrier-Functional entity reagent onto a nucleotide derivative comprising an amino group:
O
FE1-Carrier-COOH HN Carrier
15 μL of a 150 mM building block solution of FE1 -Carrier-COOH is mixed with 15 μL of a 150 mM solution of EDC and 15 μL of a 150 mM solution of N-hydroxy- succinimide (NHS) using solvents like DMF, DMSO, water, acetonitril, THF, DCM, methanol, ethanol or a mixture thereof. The mixture is left for 15 min at 25°C. 45 μL of an aminooligo (10 nmol) in 100 mM buffer at a pH between 5 and 10, preferably 6.0-7.5 is added and the reaction mixture is left for 2 hours at 25°C. Excess building block and organic by-products were removed by extraction with EtOAc (400 μL).
Remaining EtOAc is evaporated in vacuo using a speedvac. The building block is purified following elution through a BioRad micro-spin chromatography column, and analyzed by electron spray mass spectrometry (ES-MS).
Example 4 (General procedure ())
Where Oligo is 5' XCG ATG GAT GCT CCA GGT CGC 3', X = 5' amino C6 (Glen catalogued 0-1906-90), Expected molecular weight: 6313.22 MS (calc.) = 6543,43; MS (found) = 6513,68*
* Observed molecular weight of the cleaved sulfonic ester: 6513.68 Expected molecular weight of the cleaved ester: 6514.37 The quantitative loss of the ethyl group is probably due to the presence of piperidine during the recording of the LC- S data.
General Procedure 4: Loading of a carrier coupled functional entity onto an amino oligo:
25 μl 100 mM carrier coupled functional entity dissolved in DMF (dimethyl forma- ide) was mixed with 25 μl 100 mM EDC (1-ethyl-3-(3-dimethylaminopropyl) car- bodiimide hydrochloride) in DMF for 30 minutes at 25° C. The mixture was added to 50 μl amino oligo in H2O with 100 mM HEPES (2-[4-(2-hydroxy-ethyl)-piperazin-1- yl]-ethanesulfonic acid) pH 7.5 and the reaction was allowed to proceed for 20 minutes at 25° C. Unreacted carrier coupled functional entity was removed by extraction with 500 μl EtOAc (ethyl acetate), and the oligo was purified by gel filtration through a microspin column equilibrated with 100 M MES (2-(N-morpholino) ethanesulfonic acid) pH 6.0.
Oligonucleotide used:
Oligo A: 5'-YACGATGGATGCTCCAGGTCGC
Y = Amino modifier C6 (Glen# 10-1906)
Example 5 (General procedure 4)
Carrier - Functional Entity: (4-Carboxy-phenyl)-dimethyl-sulfonium
Oligo
Mass: 6789.21 (observed using ES-MS), 6790.65 (calculated)
General Procedure 5: Preparation of arylation building blocks: Functional— OH Entity C
oligo
Funtional Entity-OH is a phenol, n is an integer between 3 and 6.
Step l
To a solution of the bis-sulfonylchloride (Ward.R.B.; J.Org.Chem.; 30; 1965; 3009- 3011 ; Qiu, Weiming; Burton, Donald J.; J. Fluorine Chem.; 60; 1 ; 1993; 93-100) (3 umol) in DMF, DMSO, acetonitril, THF or a mixture thereof (150 uL) is a phenolic functional entity in excess (1.05-1.8 mmol) in DMF, DMSO, acetonitril, THF or a mixture thereof (150 uL) added slowly at temperatures between -20 °C and 100 °C preferably at 0-50 °C in the presence of a base such as TEA, DIEA, pyridine, Na- HCO3 or K2CO3.
Step2
The reaction mixture from step 1 is added to a solution of an aminooligo (10 nmol) in 100 mM buffer at a pH between 5 and 10, preferably 6.0-7.5 optionally in the presence of NHS. The reaction mixture is left for 2 hours at 25°C. Excess building block and organic by-products were removed by extraction with EtOAc (400 μL). Remaining EtOAc is evaporated in vacuo using a speedvac. The building aminooligo is purified following elution through a BioRad micro-spin chromatography column, and analyzed by electron spray mass spectrometry (ES-MS). Use of building blocks
General Procedure 6: Alkylation of oligonucleotide derivatives containing a nucleophilic recipient group using a building block of the invention:
Carrier
recipient reactive group
An oligonucleotide building block carrying functional entity FE1 is combined at 2 μM final concentration with one equivalent of a complementary building block displaying a nucleophilic recipient group. Reaction proceeds at temperatures between 0 °C and 100 °C preferably between 15 °C-50 °C for 1-48 hours, preferably 10-20 hours in DMF, DMSO, water, acetonitril, THF, DCM, methanol, ethanol or a mixture thereof, pH buffered to 4-10, preferably 6-8. Organic by-products are removed by extraction with EtOAc, followed by evaporation of residual organic solvent for 10 min in vacuo. Pd catalyst is removed and oligonucleotides are isolated by eluting sample through a BioRad micro-spin chromatography column. Coupling efficiency is quantified by ES-MS analysis.
General procedure 7: Transfer of functional entity from a carrier oligo to recipient reactive group.
A carrier coupled functional entity oligo (Example 1) (250 pmol) was added to a scaffold oligo B (200 pmol) in 50 μl 100 mM MES, pH 6. The mixture was incubated overnight at 25 °C. Subsequently, the mixture was purified by gel filtration using a microspin column equilibrated with H2O and transfer of the functional entity was veri- fied by electron spray mass spectrometry (ES-MS). Transfer efficiency is expressed in percent and were calculated by dividing the abundance of scaffold oligo carrying transferred functional entities to total abundance of scaffold oligos (with and without transferred functional entities).
Example 6 (General procedure 7)
"X" ιιγιι
Mass ("X"): 6583.97 (observed), 6583.31 (calculated). Abundance: 65.79 (arbitrary units) Mass ("Y"): 6599.73 (observed), 6597.34 (calculated). Abundance: 29.23 (arbitrary units) Mass ("Z"): 6789.36 (observed), 6790.65 (calculated)
Transfer efficiency calculated as: 29.23 / (29.23 + 65.79) = 0.3076 ~ 31 %
General Procedure 8: Arylation of oligonucleotide derivatives containing a nucleophilic recipient group using a building block of the invention:
=rec p ent reac ve group
An oligonucleotide building block carrying functional entity FE1 is combined at 2 μM final concentration with one equivalent of a complementary building block displaying a nucleophilic recipient group. In the presence of a Pd catalyst, the reaction pro- ceeds at temperatures between 0 °C and 100 °C preferably between 15 °C-50 °C for 1-48 hours, preferably 10-20 hours in DMF, DMSO, water, acetonitrile, THF, DCM, methanol, ethanol or a mixture thereof, pH buffered to 4-10, preferably 6-8. Organic by-products are removed by extraction with EtOAc, followed by evaporation of residual organic solvent for 10 min in vacuo. Pd catalyst is removed and oligonu- cleotides are isolated by eluting sample through a BioRad micro-spin chromatogra- phy column. Coupling efficiency is quantified by ES-MS analysis.
General Procedure 9: General route to the formation of alkylating/vinylating monomer building blocks with a thio-succinimid S-C-connecting group and use of these:
R1 = H, Me, Et, iPr, CI, N02 R2 = H, Me, Et, iPr, CI, N02 R1 and R2 may be used to tune the reactivity of the sulphate to allow appropriate reactivity. Chloro and nitro substitution will increase reactivity. Alkyl groups will decrease reactivity. Ortho substituents to the sulphate will due to steric reasons direct incoming nucleophiles to attack the R-group selectively and avoid attack on sulphur. E.g.
template
3-Aminophenol (6) is treated with maleic anhydride, followed by treatment with an acid e.g. H2SO4 or P2O5 and heat to yield the maleimide (7). The ring closure to the maleimide may also be achieved when an acid stable O-protection group is used by treatment with or Ac2O with or without heating, followed by O-deprotection. Alternatively reflux in Ac2O, followed by O-deacetylation in hot water/dioxane to yield (7). Further treatment of (7) with SO2CI2 with or without triethylamine or potassium carbonate in dichloromethane or a higher boiling solvent will yield the intermediate (8), which may be isolated or directly further transformed into the aryl alkyl sulphate by the quench with the appropriate alcohol, in this case MeOH, whereby (9) will be formed. The organic building block (9) may be connected to an oligo nucleotide, as follows.
A thiol carrying oligonucleotide in buffer 50 mM MOPS or hepes or phosphate pH 7.5 is treated with a 1-100 mM solution and preferably 7.5 mM solution of the organic building block (9) in DMSO or alternatively DMF, such that the DMSO/DMF concentration is 5-50%, and preferably 10%. The mixture is left for 1-16 h and preferably 2-4 h at 25 °C. To give the alkylating in this case methylating monomer building block (10).
The reaction of the alkylating monomer building block (10) with an amine carrying monomer building block may be conducted as follows:
The coding oligonucleotide (1 nmol) is mixed with a thio oligonucleotide loaded with a building block (1 nmol) (10) and an amino-oligonucleotide (1 nmol) in hepes-buffer (20 μL of a 100 mM hepes and 1 M NaCI solution, pH=7.5) and water (39 uL). The oligonucleotides are annealed to the template by heating to 50 °C and cooled (2 °C/ second) to 30 °C. The mixture is then left o/n at a fluctuating temperature (10 °C for
1 second then 35 °C for 1 second), to yield the template bound methylamine (11).
A vinylating monomer building block may be prepared and used similarily as described above for an alkylating monomer building block. Although instead of reacting the chlorosulphonate (8 above) with an alcohol, the intermediate chlorosulphate is isolated and treated with an enolate or O-trialkylsilylenolate with or without the presence of fluoride. E.g.
Formation of the vinylating monomer building block (13):
The thiol carrying oligonucleotide in buffer 50 mM MOPS or hepes or phosphate pH 7.5 is treated with a 1-100 mM solution and preferably 7.5 mM solution of the organic building block (12) in DMSO or alternatively DMF, such that the DMSO/DMF concentration is 5-50%, and preferably 10%. The mixture is left for 1-16 h and preferably 2-4 h at 25 °C. To give the vinylating monomer building block (13).
The sulfonylenolate (13) may be used to react with amine carrying monomer building block to give an enamine (14a and/or 14b) or e.g. react with an carbanion to yield (15a and/or 15b). E.g.
template (13) (14a) (14b)
template (13) (15a) (15b)
The reaction of the vinylating monomer building block (13) and an amine or nitroal- kyl carrying monomer building block may be conducted as follows: The coding oligonucleotide (1 nmol) is mixed with a oligonucleotide building block (1 nmol) (13) and an amino-oligonucleotide (1 nmol) or nitroalkyl-oligonucleotide (1 nmol) in 0.1 M TAPS, phosphate or hepes-buffer and 300 mM NaCI solution, pH=7.5-8.5 and preferably pH=8.5. The oligonucleotides are annealed to the template by heating to 50 °C and cooled (2 °C/ second) to 30 °C. The mixture is then left o/n at a fluctuating temperature (10 °C for 1 second then 35 °C for 1 second), to yield template bound (14a/b or 15a/b).
Abbreviations

Claims

Claims
1. A building block of the general formula
Complementing Element - Linker - Carrier - C-F-connecting group - Func- tional entity precursor capable of transferring a Functional entity precursor to a recipient reactive group, wherein
Complementing Element is a group identifying the Functional entity precursor, Linker is a chemical moiety comprising a spacer and a S-C-connecting group, wherein the spacer is a valence bond or a group distancing the Functional entity precursor to be transferred from the complementing element and the S-C- connecting group connects the spacer with the Carrier
Carrier is arylene, heteroarylene, C-ι-C6 alkylene, Cι-C6 alkenylene, C-|-C6 al- kynylene, or -(CF2)m- substituted with 0-3 R1 wherein m is an integer between 1 and 10;
R1 are independently selected from -H, -OR2, -NR2 2, -Halogen, -NO2, -CN, -C(Halogen)3, -C(O)R2, -C(O)NHR2, C(O)NR2 2, -NC(O)R2, -S(O)2NHR2, -S(O)2NR2 2, -S(O)2R2, -P(O)2-R2, -P(O)- R2, -S(O)- R2, P(O)-OR2, -S(O)-OR2, -N+R2 3, wherein R2 is H, C-|-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or aryl, C-F-connecting group is chosen from the group consisting of -SO2-O-,
-O-SO2-O-, -C(O)-O-, -S+(R3)-, -C-U-C(V)-O-, -P+(W)2-O-, -P(W)-O- where U is -C(R2)2-, -NR2- or -O-; V is =O or =NR2 and W is -OR2 or -N(R2)2
Functional entity precursor is -C(H)(R3)-R4 or functional entity precursor is het- eroaryl or aryl optionally substituted with one or more substituents belonging to the group comprising R3 and R4.
Wherein R3 and R4 independently is H, alkyl, alkenyl, alkynyl, alkadienyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl, optionally substituted with one or more substitu- ents selected from the group consisting of SnR5R6R7, Sn(OR5)R6R7,
Sn(OR5)(OR6)R7, BR5R6, B(OR5)R6, B(OR5)(OR6), halogen, CN, CNO, C(halogen)3, OR5, OC(=O)R5, OC(=O)OR5, OC(=O)NR5R6, SR5, S(=O)R5, S(=O)2R5, S(=O)2NR5R6, NO2, N3, NR5R6, N+R5R6R7, NR5OR6, NR5NR6R7, NR5C(=O)R6, NR5C(=O)OR6, NR5C(=O)NR6R7, NC, P(=O)(OR5)OR6, P+R5R6R7, C(=O)R5, C(=NR5)R6, C(=NOR5)R6, C(=NNR5R6), C(=O)OR5, C(=O)NR5R6, C(=O)NR5OR6, C(=O)NR5NR6R7, C(=NR5)NR6R7, C(=NOR5)NR6R7 or R8, wherein,
R5, R6, and R7 independently is H, alkyl, alkenyl, alkynyl, alkadienyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl, optionally substituted with one or more substituents selected from the group consisting of halogen, CN, CNO, C(halogen)3, =O, OR8, OC(=O)R8, OC(=O)OR8, OC(=O)NR8R9, SR8, S(=O)R8, S(=O)2R8, S(=O)2NR8R9, NO2, N3, NR8R9, N+R8R9R10, NR5OR6, NR5NR6R7, NR8C(=O)R9, NR8C(=O)OR9, NR8C(=O)NR9R10, NC, P(=O)(OR8)OR9, P+R5R6R7, C(=O)R8, C(=NR8)R9, C(=NOR8)R9, C(=NNR8R9), C(=O)OR8, C(=O)NR8R9, C(=O)NR8OR9
C(=NR5)NR6R7, C(=NOR5)NR6R7or C(=O)NR8NR9R10, wherein R5 and R6 may together form a 3-8 membered heterocyclic ring or R5 and R7 may together form a 3-8 membered heterocyclic ring or R6 and R7 may together form a 3-8 membered heterocyclic ring, wherein,
R8, R9, and R10 independently is H, alkyl, alkenyl, alkynyl, alkadienyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl and wherein R8 and R9 may together form a 3-8 membered heterocyclic ring or R8 and R10 may together form a 3-8 membered heterocyclic ring or R9 and R10 may together form a 3-8 membered heterocyclic ring.
2. A compound according to claim 1 wherein, Functional entity precursor is -C(H)(R11)-R11' or functional entity precursor is heteroaryl or aryl substituted with 0-3 R11, 0-3 R13 and 0-3 R15, wherein R11 and R11' are independently H, or selected among the group consisting of a C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C4-C8 alkadienyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, and heteroaryl, said group being substituted with 0-3 R12, 0-3 R13 and 0-3 R15, or R11 and R11' are C C3 alkylene-NR12 2, d-C3 alkylene-NR12C(O)R16, C C3 al- kylene-NR12C(O)OR16, C C2 alkylene-O-NR12 2, C C2 alkylene-O-NR12C(O)R16, CτC-2 alkylene-O-NR12C(O)OR16 substituted with 0-3 R15, where R12 is H or selected independently among the group consisting of C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, heteroaryl, said group being substituted with 0-3 R 3 and 0-3 R15,
R13 is selected independently from -N3, -CNO, -C(NOH)NH2l -NHOH, -NHNHR 7, -C(O)R17, -SnR17 3, -B(OR17)2, -P(O)(OR17)2 or the group consisting of C2-C6 alkenyl, C2-C6 alkynyl, C -C8 alkadienyl said group being substituted with 0-2 R14, where R14 is independently selected from -NO2, -C(O)OR17, -COR17, -CN, -OSiR173, -OR17 and -NR17 2; R15 is =O, -F, -CI, -Br, -I, -CN, -NO2, -OR17, -NR17 2, -NR17-C(O)R16,
-NR17-C(O)OR16, -SR17, -S(O)R17, -S(O)2R17, -COOR17, -C(O)NR17 2 and -S(O)2NR17 2, R16 is H, d-Cβ alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, aryl or C C6 alkylene-aryl substituted with 0-3 substituents independently selected from -F, -CI, - NO2, -R2, -OR2, -SiR2 3; R17 is selected independently from H, al-
kylene-aryl, G is H or C Q6 alkyl and n is 1 ,2,3 or 4.
3. A compound according to claim 2 wherein, Functional entity precursor is -C(H)(R11)-R11' or functional entity precursor is heteroaryl or aryl substituted with 0-3 R11, 0-3 R13 and 0-3 R15, wherein
R11 and R11' are independently H, or selected among the group consisting of a alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C4-C8 alkadienyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, and heteroaryl, said group being substituted with 0-3 R12, 0-3 R13 and 0-3 R15, or R11 and R11' are C C3 alkylene-NR12 2, C C3 alkylene-NR12C(O)R16, C C3 al- kylene-NR12C(O)OR16, C C2 alkylene-O-NR12 2, C C2 alkylene-O-NR12C(O)R16, d-C2 alkylene-O-NR12C(O)OR16 substituted with 0-3 R15, where R12 is H or selected independently among the group consisting of C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, heteroaryl, said group being substituted with 0-3 R13 and 0-3 R15,
R13 is selected independently from -N3, -CNO, -C(NOH)NH2, -NHOH, -NHNHR17, -C(O)R17, -SnR17 3, -B(OR17)2, -P(O)(OR17)2 or the group consisting of C2-C6 alkenyl, C2-C6 alkynyl, C4-C8 alkadienyl said group being substituted with 0-2 R14, where R14 is independently selected from -NO2, -C(O)OR17, -COR17, -CN,
-OSiR17 3, -OR17 and -NR17 2;
R15 is =O, -F, -CI, -Br, -I, -CN, -NO2, -OR17, -NR17 2, -NR17-C(O)R16, -NR17-C(O)OR16, -SR17, -S(O)R17, -S(O)2R17, -COOR17, -C(O)NR17 2 and -S(O)2NR17 2, R16 is H, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, aryl or CrC6 alkylene-aryl substituted with 0-3 substituents independently selected from -F, -CI, - NO2, -R2, -OR2, -SiR2 3; wherein R17 is selected independently from H, C C6 alkyl, C3-C7 cycloalkyl, aryl, C-ι-C-6 alkylene-aryl.
4. A compound according to claim 1 wherein, Functional entity precursor is
-C(H)(R 1)-R11' wherein
R11 and R11' are or C C3 alkylene-NR12 2, C C3 alkylene-NR12C(O)R16, C C3 al- kylene-NR1 C(O)OR16, C C2 alkylene-O-NR12 2, C C2 alkylene-O-NR12C(O)R16, d-C2 alkylene-O-NR1 C(O)OR16 substituted with 0-3 R15
5. A compound according to claim 1 wherein, Functional entity precursor is
-C(H)(R11)-R11' wherein R11 and R11' are independently H, or selected among the group consisting of a C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C4-C8 alkadienyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, and heteroaryl, said group being substituted with 0-3 R12, 0-3 R13 and 0-3 R15,
6. A compound according to claim 2 wherein, Functional entity precursor is
-C(H)(R11)-R11, wherein
R11 and R11' are independently H, or selected among the group consisting of a C C6 alkyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, and heteroaryl, said group being substituted with 0-3 R12 and 0-3 R15, where R12 is H or selected independently among the group consisting of C-ι-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C3-C7 cycloheteroalkyl, aryl, heteroaryl.
R15 is =O, -F, -CI, -Br, -I, -CN, -NO2, -OR17, -NR17 2, -NR17-C(O)R16, -NR17-C(O)OR16, -SR17, -S(O)R17, -S(O)2R17, -COOR17, -C(O)NR17 2 and -S(O)2NR17 2, R17 is selected independently from H, C^Ce alkyl, C3-C7 cycloalkyl, C C6 alkylene-aryl,
7. A compound according to claim 1 wherein, Functional entity precursor is heteroaryl or aryl substituted with 0-3 R11, 0-3 R 3 and 0-3
8. A compound according to claim 2 wherein C-F-connecting group is chosen from the group consisting of -SO2-O-, -O-SO2-O-, -C(O)-O-, -S+(R11)-, -C-U-C(V)-O-, -P+( )2-O-, and -P(W)-O- where U is -C(R2)2-, -NR2- or -O-; V is =O or =NR2 and W is -OR2 or -N(R )2
9. A compound according to claim 2 wherein C-F-connecting group is -S+(R11)-,
10. A compound according to claims 1 - 2 wherein C-F-connecting group is chosen from the group consisting of -SO2-O-, -O-SO2-O-, -C(O)-O-, -S+(R17)-, -C-U- C(V)-O-, -P+(W)2-O-, and -P(W)-O- where U is -C(R2)2-, -NR2- or -O-; V is =O or
=NR2 and W is -OR2 or -N(R )2, wherein R17 is selected independently from H, C C6 alkyl, C3-C7 cycloalkyl, aryl, C C6 alkylene-aryl.
11. A compound according to claims 1 - 2 wherein C-F-connecting group is cho- sen from the group consisting of -SO2-O-, and -S+(R17)-; wherein R17 is selected independently from H, C C6 alkyl, C3-C7 cycloalkyl, aryl, C C6 alkylene-aryl.
12. A compound according to claim 1 wherein, Spacer is a valence bond, C-i-C6 alkylene-A-, C2-C6 alkenylene-A-, C2-C6 alkynylene-A-, or
said spacer optionally being connected through A to a linker selected from
— (CH2)n-S-S-(CH2)m-B— where A is a valence bond, -C(O)NR17-, -NR17-, -O-, -S-, or -C(O)-O-; B is a va- lence bond, -O-, -S-, -NR17- or -C(O)NR17- and connects to S-C-connecting group; and n and m independently are integers ranging from 1 to 10; and R17 is selected independently from H, C C6 alkyl, C3-C7 cycloalkyl, aryl, or C C6 alkylene-aryl
13. A compound according to claim 1 wherein, Spacer is a valence bond, C C6 alkylene-A-, C2-C6 alkenylene-A-, C2-C6 alkynylene-A-, or said spacer optionally being connected through A to a linker selected from
where A is a valence bond, -C(O)NR17-, -NR17-, -S-, or -C(O)-O-; B is -O-, -S-, -NR17-, or -C(O)NR17- and connects to S-C-connecting group; and n and m independently are integers ranging from 1 to 6; and R17 is selected independently from H, C-|-C6 alkyl, C3-C7 cycloalkyl, aryl, or C C6 alkylene-aryl
14. A compound according to claim 1-2 wherein, S-C-connecting group is a va-
alkylene) — lence bond, -NH-C(=O)-, -NH-SO2-, -S-S-,
15. A compound according to claim 2 wherein, the carrier is selected from the group consisting of arylene, heteroarylene or -(CF2)m. substituted with 0-3 R1 wherein m is an integer between 1 and 10, and C-F-connecting group is -SO2-O-, and the functional entity precursor is -C(H)(R11)-R11'.
16. A compound according to claim 2 wherein, the carrier is -(CF2)m- wherein m is an integer between 1 and 10, the C-F-connecting group is -SO2-O-; and the functional entity precursor is aryl or heteroaryl substituted with 0-3 R11, 0-3 R13 and 0-3 R15.
17. A compound according to claims 1-16 wherein Complementing element is a nucleic acid.
18. A compound according to claims 1-16 where Complementing element is a se- quence of nucleotides selected from the group of DNA, RNA, LNA PNA, or mor- pholino derivatives.
19. A library of compounds according to claim 1 , wherein each different member of the library comprises a complementing element having a unique sequence of nu- cleotides, which identifies the functional entity.
20. A method for transferring a functional entity precursor to a recipient reactive group, comprising the steps of providing one or more building blocks according to claims 1 to 18, contacting the one or more building blocks with a corresponding encoding element associated with a recipient reactive group under conditions which allow for a recognition between the one or more complementing elements and the encoding elements, said contacting being performed prior to, simultaneously with, or subsequent to a transfer of the functional entity precursor to the recipient reactive group.
21. The method according to claim 20, wherein the encoding element comprises one or more encoding sequences comprised of 1 to 50 nucleotides and the one or more complementing elements comprises a sequence of nucleotides complementary to one or more of the encoding sequences.
22. The method of claims 20 or 21 , wherein the recipient reactive group is a nucleophilic S- or N- atom, which may be part of a chemical scaffold, and the activating catalyst is contains palladium.
EP03711855A 2002-03-15 2003-03-14 A building block forming a c-c or a c-hetero atom bond upon reaction Withdrawn EP1487850A2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US36405602P 2002-03-15 2002-03-15
US364056P 2002-03-15
DKPA200200415 2002-03-15
DK200200415 2002-03-15
US43442302P 2002-12-19 2002-12-19
DK200201950 2002-12-19
US434423P 2002-12-19
DKPA200201950 2002-12-19
PCT/DK2003/000176 WO2003078446A2 (en) 2002-03-15 2003-03-14 A building block forming a c-c or a c-hetero atom bond upon reaction

Publications (1)

Publication Number Publication Date
EP1487850A2 true EP1487850A2 (en) 2004-12-22

Family

ID=28046589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03711855A Withdrawn EP1487850A2 (en) 2002-03-15 2003-03-14 A building block forming a c-c or a c-hetero atom bond upon reaction

Country Status (4)

Country Link
US (1) US20050247001A1 (en)
EP (1) EP1487850A2 (en)
AU (1) AU2003218629A1 (en)
WO (1) WO2003078446A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332896A3 (en) 2001-03-19 2012-09-26 President and Fellows of Harvard College Evolving new molecular function
EP1401850A1 (en) 2001-06-20 2004-03-31 Nuevolution A/S Nucleoside derivatives for library preparation
CA2518626A1 (en) 2002-03-15 2003-09-25 Nuevolution A/S An improved method for synthesising templated molecules
US10730906B2 (en) 2002-08-01 2020-08-04 Nuevolutions A/S Multi-step synthesis of templated molecules
EP1540013B1 (en) 2002-08-19 2015-07-08 The President and Fellows of Harvard College Evolving new molecular function
CN1720331B (en) 2002-10-30 2013-01-02 纽韦卢森公司 Method for synthesizing bifunctional complexes
EP1756277B1 (en) 2002-12-19 2009-12-02 Nuevolution A/S Quasirandom structure and function guided synthesis methods
EP1597395A2 (en) 2003-02-21 2005-11-23 Nuevolution A/S Method for producing second-generation library
DK2236606T3 (en) 2003-03-20 2014-02-10 Nuevolution As Coding of small molecules by ligation
DK1670939T3 (en) 2003-09-18 2010-03-01 Nuevolution As Method for obtaining structural information on a coded molecule and method for selecting compounds
US7972994B2 (en) 2003-12-17 2011-07-05 Glaxosmithkline Llc Methods for synthesis of encoded libraries
CN101864412A (en) 2003-12-17 2010-10-20 普雷西斯药品公司 The method of synthesis of encoded libraries
WO2005090566A2 (en) 2004-03-22 2005-09-29 Nuevolution A/S Ligational encoding using building block oligonucleotides
CA2626325A1 (en) 2005-10-28 2007-05-10 Praecis Pharmaceuticals Incorporated Methods for identifying compounds of interest using encoded libraries
LT2341140T (en) 2005-12-01 2017-11-10 Nuevolution A/S Enzymatic encoding methods for efficient synthesis of large libraries
NZ594420A (en) 2009-02-13 2013-06-28 Chem Inc X Methods of creating and screening dna-encoded libraries
US11225655B2 (en) 2010-04-16 2022-01-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
ES2675111T3 (en) 2011-09-07 2018-07-06 X-Chem, Inc. Methods for tagging libraries with DNA coding
CN104685115A (en) 2012-07-13 2015-06-03 X-化学有限公司 DNA-encoded library with polymerase-unreadable coding oligonucleotide ligation
WO2017218293A1 (en) 2016-06-16 2017-12-21 Richard Edward Watts Oligonucleotide directed and recorded combinatorial synthesis of encoded probe molecules
US11795580B2 (en) 2017-05-02 2023-10-24 Haystack Sciences Corporation Molecules for verifying oligonucleotide directed combinatorial synthesis and methods of making and using the same
TWI827677B (en) 2018-09-18 2024-01-01 美商尼坎醫療公司 Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763281A (en) * 1970-06-26 1973-10-02 Stauffer Chemical Co Ureidoalkylphosphonates
US4822731A (en) * 1986-01-09 1989-04-18 Cetus Corporation Process for labeling single-stranded nucleic acids and hybridizaiton probes
CA2118806A1 (en) * 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2160016C (en) * 1993-04-12 2008-06-03 Robert L. Letsinger Method of forming oligonucleotides
US5681943A (en) * 1993-04-12 1997-10-28 Northwestern University Method for covalently linking adjacent oligonucleotides
US5473060A (en) * 1993-07-02 1995-12-05 Lynx Therapeutics, Inc. Oligonucleotide clamps having diagnostic applications
US5571903A (en) * 1993-07-09 1996-11-05 Lynx Therapeutics, Inc. Auto-ligating oligonucleotide compounds
US6165778A (en) * 1993-11-02 2000-12-26 Affymax Technologies N.V. Reaction vessel agitation apparatus
US5503805A (en) * 1993-11-02 1996-04-02 Affymax Technologies N.V. Apparatus and method for parallel coupling reactions
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5843650A (en) * 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
US5830658A (en) * 1995-05-31 1998-11-03 Lynx Therapeutics, Inc. Convergent synthesis of branched and multiply connected macromolecular structures
US5780613A (en) * 1995-08-01 1998-07-14 Northwestern University Covalent lock for self-assembled oligonucleotide constructs
US6258558B1 (en) * 1997-01-21 2001-07-10 The General Hospital Corporation Method for selection of proteins using RNA-protein fusions
EP0985032B2 (en) * 1997-05-28 2009-06-03 Discerna Limited Ribosome complexes as selection particles for in vitro display and evolution of proteins
GB9815163D0 (en) * 1998-07-13 1998-09-09 Brax Genomics Ltd Compounds
US6143503A (en) * 1998-04-17 2000-11-07 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
IL147037A0 (en) * 1999-07-27 2002-08-14 Phylos Inc Peptide acceptor ligation methods
WO2001016151A1 (en) * 1999-08-27 2001-03-08 Japan Science And Technology Corporation Reversible photocoupling nucleic acid and phosphoroamidite
EP2332896A3 (en) * 2001-03-19 2012-09-26 President and Fellows of Harvard College Evolving new molecular function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03078446A2 *

Also Published As

Publication number Publication date
US20050247001A1 (en) 2005-11-10
WO2003078446A3 (en) 2003-12-31
AU2003218629A1 (en) 2003-09-29
WO2003078446A2 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
WO2003078446A2 (en) A building block forming a c-c or a c-hetero atom bond upon reaction
US20070213519A1 (en) Building Block Forming A C=C Double Bond Upon Reaction
KR101032008B1 (en) Polynucleotide labeling reagents
WO2003078626A2 (en) A building block capable of transferring a functional entity
EP1490384A2 (en) A building block forming a c-c bond upon reaction
CA2451524A1 (en) Templated molecules and methods for using such molecules
CN101861318A (en) Method for synthesizing morpholino oligomers
CN102076703B (en) Process for the manufacture of oligonucleotides
AU752521B2 (en) Cyclohexyl and heterocyclyl nucleoside derivatives, method for producing these derivatives, and the use of the derivatives and their oligomers or conjugates in pairing and/or testing systems
AU2006316903B8 (en) Polynucleotide labelling reagent
US20020103365A1 (en) Process for the synthesis of nucleic acids on a solid support and compounds which are useful in particular as solid supports in the said process
HK1126224B (en) Polynucleotide containing a phosphate mimetic
HK1126183B (en) Polynucleotide labelling reagent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GODSKESEN, MICHAEL, ANDERS

Inventor name: FELDING, JAKOB

Inventor name: SAMS, CHRISTIAN

Inventor name: LUNDORF, MIKKEL, DYBRO

Inventor name: JENSEN, KIM, BIRKEBAERD

Inventor name: PEDERSEN, HENRIK

Inventor name: GOULIAEV, ALEX, HAAHR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060801